Table 1.

FDA Approved Indications for the Oral Liquid Suspension of Spironolactone

Indication	Aim
● Heart failure with reduced ejection fraction, NYHA class III-IV	To increase survival, manage edema, and to reduce the need for hospitalization for heart failure
● Hypertension as add-on therapy	To lower blood pressure in adult patients who are not adequately controlled on other agents
● Edema caused by cirrhosis	To manage edema that is not responsive to fluid and sodium restriction

Notes: N.B.: Patients requiring a dose >100 mg should not use spironolactone oral suspension (25 mg/5 mL) as this is not therapeutically equivalent to spironolactone tablets; doses of the suspension >100 mg may result in spironolactone concentrations higher than expected.

Abbreviations: FDA, Food and Drug Administration; NYHA, New York Heart Association.